Eli Lilly v. Henry Meds: What the Lawsuit Means for Compounded Tirzepatide Patients

You searched lilly henry meds lawsuit. You probably want to know whether your medication is at risk, what Eli Lilly actually alleges, and whether it is time to switch providers.

Two facts to anchor on. First, Lilly filed suit against Henry Meds' parent, Adonis Health Inc., in the U.S. District Court for the Northern District of California on April 23, 2025 (Case No. 3:25-cv-0353). Second, on September 24, 2025, Judge Jon S. Tigar allowed Lilly's false-advertising claim about "personalized" marketing to proceed and dismissed the safe-and-effective claim with leave to amend.

Henry Meds is still operating as of May 2026. No injunction. No recall. For an alternative-provider shortlist that ranks across both molecules, see best online GLP-1 programs in 2026; if you want the safety-first list, see our list of verified-safe alternatives to Henry Meds, ranked by safety and regulatory posture rather than headline price.

This article walks through what Lilly alleges, what the September ruling actually decided, why the "personalized" claim is the structural fight, why the oral tirzepatide tablet is a separate problem, and how to read the same marketing pattern at any compounded GLP-1 provider.

What Eli Lilly Alleges in the Complaint

"No Injection, Same Active Ingredient as Mounjaro® and Zepbound®." That exact line, from Henry Meds' May 28, 2024 BusinessWire press release announcing oral tirzepatide dissolvable tablets, sits at the center of Lilly's complaint.

Lilly groups its allegations into four buckets. First, comparative claims that link Henry's compounded products directly to Mounjaro and Zepbound, including the "same active ingredient" language. Second, "personalized," "individualized," "tailored," and "patient-specific" framing applied to what Lilly says is a standardized formula shipped to all patients at the same dose. Third, sale of tirzepatide in pill and drop forms, formats Lilly describes as having "never been studied or approved by the FDA." Fourth, trading on Lilly's clinical-trial reputation, which the complaint describes as "Lilly's credibility, earned through decades of safe and effective pharmaceutical manufacturing and years of clinical research and testing on tirzepatide specifically."

The legal hooks are three. The Lanham Act (federal false advertising), California's Unfair Competition Law, and California's False Advertising Law. The case caption is Eli Lilly and Co. v. Adonis Health Inc. d/b/a Henry Meds, Case No. 3:25-cv-0353, N.D. Cal., filed April 23, 2025. Adonis Health is Henry Meds' legal entity, headquartered in San Francisco.

Note the framing: Lilly alleges, the complaint claims. Nothing here has been adjudicated on the merits.

The September 2025 Ruling: What Survived, What Got Dismissed

On September 24, 2025, U.S. District Judge Jon S. Tigar issued his ruling on Henry Meds' motion to dismiss. The order split the case in two.

The personalization claim proceeds. Tigar found Lilly plausibly alleged that Henry's use of "individualized," "tailored," and "patient-specific" was "literally false," the threshold the Lanham Act requires for a presumption of damages. If patients receive the same formula at the same dose, the personalization label moves from "unsupported" to "literally false." That distinction matters because literal falsity strengthens Lilly's discovery posture and limits Henry's defenses going forward.

The safe-and-effective claim was dismissed with leave to amend. Tigar found that Lilly's allegations about "safe and effective" marketing pointed at a lack of substantiation rather than affirmative falsity. Lilly may refile this claim if it can produce evidence the marketing was actually false, not merely unsupported by clinical-trial data.

Standing was settled in Lilly's favor. The court rejected Henry's argument that it operated in a different supply-chain segment. Tigar wrote that "Henry's advertising itself draws direct comparisons between Lilly's FDA-approved tirzepatide medications and Henry's compounded tirzepatide products." That same finding is what distinguished this case from Lilly v. Willow Health (covered in Section 6), which was dismissed.

Current status: the henry meds lilly suit is in active discovery on the personalization claim. No injunction has issued.

Why "Personalized" Is the Load-Bearing Claim

A marketing dispute over the word "personalized" is normally a legal headache, not an existential threat. For Henry Meds, it is closer to existential. The reason has nothing to do with Lanham Act damages and everything to do with pharmacy law.

The regulatory pathway works like this. 503A pharmacies are state-licensed and may compound for individual patients with valid prescriptions. A 503A compound is legal if (a) it is patient-specific, (b) it is not "essentially a copy" of a commercially available product, and (c) the underlying drug is on FDA shortage or the patient has a documented medical need the commercial product cannot meet. The FDA declared the tirzepatide shortage resolved on December 19, 2024. The shortage exception ended.

Wind-down deadlines followed. 503A pharmacies had until February 18, 2025. 503B outsourcing facilities had until March 19, 2025. After those dates, mass compounding of tirzepatide became illegal absent documented patient-specific medical necessity. Cost savings and insurance denial do not qualify. Our full 503A pharmacy framework walks through the documentation a compliant provider should be generating.

Tie this back to the lawsuit. If Henry's compounds are genuinely patient-specific, 503A still arguably covers them, which is the heart of Henry's defense. If Lilly proves the products are standardized (the core of the personalization claim), the 503A cover collapses on the same facts. The marketing claim and the regulatory defense rise and fall on the same evidence.

The Oral Tirzepatide Pill: A Separate Red Flag

The FDA has never approved any oral form of tirzepatide. Only injectable Mounjaro (type 2 diabetes) and injectable Zepbound (weight management, obstructive sleep apnea) carry approval. The Henry Meds oral tirzepatide ODT, launched May 2024, has no FDA-approved analog.

The science is unkind to oral tablets. Tirzepatide is a peptide of approximately 4,813 daltons. Peptides of that size are typically broken down by gastric acid and digestive enzymes before reaching the bloodstream. Estimated bioavailability of oral tirzepatide sits under 10%, against roughly 80% for the injectable. Oral semaglutide (a different molecule) needs about 14x the milligram dose of injectable forms and only works because of a specialized delivery agent called SNAC. No comparable delivery technology exists for oral tirzepatide. No peer-reviewed clinical-trial data exists on the absorption or efficacy of any compounded oral tirzepatide product.

A parallel case is now testing this directly. In November 2025, a class action was filed against OpenLoop Health and Triad Rx alleging that compounded oral tirzepatide is therapeutically inert. The OpenLoop suit is separate from Lilly v. Henry Meds, but it targets the same product category.

If you are on henry meds oral tirzepatide ODTs specifically, the regulatory and pharmacological basis is materially weaker than for injectable compounded GLP-1s. The compounded tirzepatide lawsuit on the marketing side and the OpenLoop suit on the science side now bracket the same product from two directions.

The Wider Pattern: Mochi, Fella, Willow, and the FDA

On April 23, 2025, Lilly filed four nearly-simultaneous lawsuits in federal court. Mochi Health, Fella Health/Delilah, Henry Meds, and Willow Health Services were all sued the same day. Compounded GLP-1 enforcement is not a one-bad-actor story.

Status of each as of May 2026:

• Willow Health Services (No. 2:25-cv-03570). Dismissed without prejudice on September 8, 2025 by Judge Andre Birotte Jr. Lilly could not show patient or physician diversion, and Willow's "personalized" claims were treated as opinion rather than actionable misrepresentation.
• Mochi Health (No. 3:25-cv-03534). First motion to dismiss granted October 2025. Lilly amended. Judge Jacqueline Scott Corley partially denied the renewed motion and allowed UCL and Lanham Act claims to proceed. Lilly cited the Tigar ruling in its Mochi briefing the same day Tigar's order issued.
• Fella Health / Aios Inc. (No. 3:25-cv-03535). Active. Lilly alleges Fella switched patients en masse onto formulations with l-arginine or glycine additives without combination testing.

Folded into this picture is the FDA. On September 16, 2025, the agency issued more than 55 warning letters to telehealth sellers of compounded GLP-1 medications, citing "same active ingredient" marketing as a primary violation. On March 3, 2026, the FDA released a second batch of 30 warning letters with the same pattern. Henry Meds is not publicly confirmed in either batch.

What Current Henry Meds Patients Should Consider

Do not panic. The lawsuit is a marketing dispute, not a safety recall. As of May 2026, Henry Meds continues to ship medication, no injunction has been entered, and no FDA warning letter to Henry Meds has been publicly confirmed.

Three documented signals sit alongside the lawsuit:

1. BBB rating of F. Adonis Health Inc. is not BBB accredited. 192 complaints in three years. The F is specifically because Henry Meds failed to respond to 25-plus complaints, the BBB's stated reason for the rating. Most complaints cluster on auto-renewal billing and cancellation, not medication safety. Our deep dive on Henry Meds' BBB and Trustpilot record breaks down the complaint themes.
2. Trustpilot review-authenticity flag. Trustpilot has flagged the Henry Meds page with a notice indicating suspected inauthentic review patterns, warranting a discount on the volume-weighted 4.5-star rating across 12,320-plus reviews.
3. Pharmacy switching without notice. Multiple ConsumerAffairs and BBB reports describe receiving medication from a different compounding pharmacy mid-subscription, with measurable changes in effectiveness. Henry Meds does not publicly disclose its pharmacy partners.

A simple framework. On injectable compounded semaglutide or tirzepatide, the lawsuit alone is not a switch trigger. On oral tirzepatide ODTs, the absence of FDA approval and bioavailability data plus the parallel OpenLoop class action are independent reasons to question the product. For unresolved billing disputes, escalate through your state attorney general or card issuer's chargeback process.

File a MedWatch report at fda.gov/safety/medwatch for any quality issues or adverse events. Those reports feed directly into FDA's enforcement evidence.

How to Spot the Same Marketing Pattern at Other Compounders

The language Lilly's complaint and the FDA warning letters target is industry-wide, not Henry-specific. Use this as a checklist when evaluating any compounded GLP-1 provider:

• "Same active ingredient as Mounjaro® / Zepbound® / Wegovy® / Ozempic®": the exact comparative phrasing FDA warning letters and Lilly's complaint flag.
• "Personalized," "individualized," "tailored," "patient-specific" without disclosure that the same formula ships to every patient at the same dose.
• Trial-data references to FDA-approved drugs ("clinically proven," "15% weight loss in studies") without distinguishing whether the cited trial used the branded drug or the compound.
• Oral, sublingual, drop, or pill formats of tirzepatide. No FDA-approved oral tirzepatide exists, and no clinical bioavailability data supports therapeutic equivalence.
• No public compounding pharmacy disclosure. Patients cannot verify your provider's pharmacy, 503A status, batch testing, or licensure.
• No documented medical-necessity workflow. After February-March 2025, 503A compounding of tirzepatide requires documented patient-specific necessity. If the intake form does not ask about ingredient allergies or commercial-product contraindications, the necessity documentation likely is not being created.
• BBB rating below B with low complaint-response rate. Independent of medication quality, this signals the company will not meaningfully respond if you have a billing or quality issue.

Pattern recognition is more durable than any single court ruling.

The Bottom Line

Lilly's case against Henry Meds is active, not decided. The September 2025 ruling on the "personalized" claim matters because the regulatory cover for compounding tirzepatide stands on the same word. Oral tirzepatide tablets sit on weaker ground than the injectables, regardless of how the lawsuit ends. The specific marketing phrases the FDA and Lilly flag are the more durable takeaway, useful at every compounded GLP-1 provider, not just this one. For providers ranked by safety and regulatory posture rather than headline price, start there.

FAQ

Is Henry Meds in trouble?

Henry Meds is the defendant in an active false-advertising suit (No. 3:25-cv-0353, N.D. Cal.), holds a BBB F rating with 192 complaints, and Trustpilot has flagged its review page for suspected inauthentic patterns. The lawsuit is unresolved and is a marketing dispute, not a safety recall. Henry Meds continues to ship medication as of May 2026.

Will Henry Meds stop shipping medication?

Not as of May 2026. No court injunction has been issued, and only an injunction or FDA enforcement action would immediately stop supply. Monitor PACER (Case No. 3:25-cv-0353) and the FDA warning-letter database for action against Adonis Health Inc.

Is Henry Meds' compounded tirzepatide safe?

The court dismissed Lilly's safe-and-effective claim with leave to amend, so safety has not been judicially settled. The FDA logged 545 adverse events for compounded tirzepatide and 605 for compounded semaglutide as of July 31, 2025, across all sellers. Injectable formulations have stronger pharmacological backing than the oral ODT.

What happens if Eli Lilly wins?

A Lanham Act injunction would likely restrict marketing language ("personalized," "same active ingredient as Mounjaro®") but would not automatically halt compounding. Combined with the post-shortage compounding ban from February and March 2025, a Lilly win would constrain Henry Meds' market position and force a business-model rewrite.